Regulatory authorities across the world have been focusing on safeguarding global supply chains. Juan Torrijos Lopez, GMP consultant at Rephine provides some practical pointers as to how pharmaceutical manufacturers and their partners should respond to evolving expectations.
In the wake of the COVID-19 pandemic, not to mention other high-profile challenges to supply chain continuity (including the Ukraine war, and the Suez Canal obstruction of March 2021, as well as Brexit in the UK/EU), major health authorities around the world have been issuing new recommendations to Life Sciences manufacturers and their supply chain partners to ensure that in the future vital drug supplies remain continuously, safely and conveniently available to the patients that need them, right around the world.